Michael Partridge | SVP of IR |
Charles Wagner | Executive VP & CFO |
Jeffrey Leiden | Chairman, CEO & President |
Paul Silva | Senior VP & Corporate Controller |
Reshma Kewalramani | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer |
Stuart Arbuckle | Executive VP & Chief Commercial Officer |
Geoff Meacham | Barclays |
Phil Nadeau | Cowen & Company |
Michael Yee | Jefferies |
Alethia Young | Cantor Fitzgerald |
Ying Huang | BoA Merrill Lynch |
Geoffrey Porges | SVB Leerink |
Brian Abrahams | RBC Capital Markets |
Cory Kasimov | JPMorgan |
Paul Matteis | Stifel |
Ravi Mehrotra | Evercore ISI |
Hartaj Singh | Oppenheimer & Company |
Brian Skorney | Baird |
Alan Carr | Needham and Company |
Welcome. This is Michael Partridge, Senior Vice President of Investor Relations. Tonight, we will review with you Vertex's business progress and provide our First Quarter Financial Results. Making prepared remarks on the call tonight, we have Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and I would like to welcome to the call Charlie Wagner, Vertex's new Chief Financial Officer.